BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 34782661)

  • 1. Immune classification and identification of prognostic genes for uveal melanoma based on six immune cell signatures.
    Gao G; Yu Z; Zhao X; Fu X; Liu S; Liang S; Deng A
    Sci Rep; 2021 Nov; 11(1):22244. PubMed ID: 34782661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of molecular subtyping system and four-gene prognostic signature with immune-related genes for uveal melanoma.
    Xia F; Yu Z; Deng A; Gao G
    Exp Biol Med (Maywood); 2022 Feb; 247(3):246-262. PubMed ID: 34743576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comprehensive Prognostic and Immunological Analysis of a Six-Gene Signature Associated With Glycolysis and Immune Response in Uveal Melanoma.
    Liu J; Lu J; Li W
    Front Immunol; 2021; 12():738068. PubMed ID: 34630418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of an immune and stromal prognostic signature in uveal melanoma to guide clinical therapy.
    Gong Q; Wan Q; Li A; Yu Y; Ding X; Lin L; Qi X; Hu L
    Aging (Albany NY); 2020 Oct; 12(20):20254-20267. PubMed ID: 33100273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated analyses identify potential prognostic markers for uveal melanoma.
    Ni Y; Zhang Z; Chen G; Long W; Tong L; Zeng J
    Exp Eye Res; 2019 Oct; 187():107780. PubMed ID: 31469983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative Splicing Events as Indicators for the Prognosis of Uveal Melanoma.
    Wan Q; Sang X; Jin L; Wang Z
    Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32098099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
    Liu D; Yang X; Wu X
    Front Immunol; 2021; 12():663495. PubMed ID: 34025664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic values of m6A RNA methylation regulators in uveal melanoma.
    Tang J; Wan Q; Lu J
    BMC Cancer; 2020 Jul; 20(1):674. PubMed ID: 32682400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Prognostic alternative splicing signatures and their clinical significance in uveal melanoma.
    Zhou W; Fei P; Li J
    Exp Eye Res; 2021 Aug; 209():108666. PubMed ID: 34129849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Identification and Validation of a Robust Immune-Associated Gene Signature in Cutaneous Melanoma.
    Song LB; Luan JC; Zhang QJ; Chen L; Wang HY; Cao XC; Song NH; Lu Y
    J Immunol Res; 2021; 2021():6686284. PubMed ID: 33688507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of deregulated microRNAs in uveal melanomas.
    Falzone L; Romano GL; Salemi R; Bucolo C; Tomasello B; Lupo G; Anfuso CD; Spandidos DA; Libra M; Candido S
    Mol Med Rep; 2019 Apr; 19(4):2599-2610. PubMed ID: 30816460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative analysis identifies key genes related to metastasis and a robust gene-based prognostic signature in uveal melanoma.
    Lei S; Zhang Y
    BMC Med Genomics; 2022 Mar; 15(1):61. PubMed ID: 35300699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel 8-Gene Prognostic Signature for Survival Prediction of Uveal Melanoma.
    Tang Z; Cai K
    Anal Cell Pathol (Amst); 2021; 2021():6693219. PubMed ID: 34434692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High EIF4E2 expression is an independent prognostic risk factor for poor overall survival and recurrence-free survival in uveal melanoma.
    Yang B; Gu A; Wu Y
    Exp Eye Res; 2021 May; 206():108558. PubMed ID: 33785306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel lncRNA-miRNA-mRNA competitive endogenous RNA network for uveal melanoma prognosis constructed by weighted gene co-expression network analysis.
    Yu H; Cheng Y; Li W; Li Z; Wu P; Qiu S; Zeng B; Huang B
    Life Sci; 2020 Nov; 260():118409. PubMed ID: 32926921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of a CD8+ T Cell Infiltration-Related Signature for Melanoma Patients.
    Yuan Y; Zhu Z; Lan Y; Duan S; Zhu Z; Zhang X; Li G; Qu H; Feng Y; Cai H; Song Z
    Front Immunol; 2021; 12():659444. PubMed ID: 34040608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of survival-related genes and a novel gene-based prognostic signature involving the tumor microenvironment of uveal melanoma.
    Lei S; Zhang Y
    Int Immunopharmacol; 2021 Jul; 96():107816. PubMed ID: 34162166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological analyses reveal an immune subtype of uveal melanoma with a poor prognosis.
    Pan H; Lu L; Cui J; Yang Y; Wang Z; Fan X
    Aging (Albany NY); 2020 Jan; 12(2):1446-1464. PubMed ID: 31954372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel four‑snoRNA signature for predicting the survival of patients with uveal melanoma.
    Yi Q; Zou WJ
    Mol Med Rep; 2019 Feb; 19(2):1294-1301. PubMed ID: 30569172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.